explore -WSS

explore

author：Wikipedia 2025-08-12 08:27:04 - browse：7

Home health and hospice chain Amedisys has chosen a new corporate owner.

Amedisys and UnitedHealth Group’s Optum agreed to a deal Monday in which UnitedHealth will pay $101 per share in cash for Amedisys, totaling $3.3 billion. UnitedHealth’s latest offer is $1 per share higher than what it proposed in its unsolicited buyout offer a few weeks ago.

Option Care Health, a company that delivers intravenous medicines and mails health care supplies to people’s homes, originally offered to acquire Amedisys in May in an all-stock deal. However, the attractiveness of that deal deteriorated after Option Care’s stock price plummeted soon after the company made its bid.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： Doctors find melanoma drugs effective against rare brain cancer

focus

WSS

Google and Epic fight stronger regulation of AI in health care

AI can’t replace a physician’s gut feeling

Menendez indictment could see pharma lose a key ally

After a drawn out lobbying fight, ARPA

Cosmetics set for new safety regulation. Why the industry is on board

Sanders adds drug shortage policies to pandemic preparedness bill

entertainment

explore

hotspot

What does generative AI mean for health care? We asked experts

How one patient went off dialysis — and others can too

Anesthesiologist group: stop taking Ozempic before surgery

Cosmetics set for new safety regulation. Why the industry is on board

The high cost of giving birth even with insurance

Medicaid, Medicare dual

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Google and Epic fight stronger regulation of AI in health care

In Memoriam: Notable people who died in 2023

Sudafed saga points to U.S. issues with evaluating older drugs

focus

Menendez indictment could see pharma lose a key ally

Detailed data confirm benefits, risks of Eli Lilly's Alzheimer's drug

https://cbu01.alicdn.com/img/ibank/2017/876/324/4403423678_1263693943.220x220xz.jpg

At Orexo, a ‘turning point’ for everything but digital health

Inequities make cancer less preventable for women: report

Sudafed saga points to U.S. issues with evaluating older drugs

hotspot

focus

hotspot

focus